Liposarcoma Multimodality Management and Future Targeted Therapies

被引:110
|
作者
Crago, Aimee M. [1 ,2 ,3 ]
Dickson, Mark A. [1 ,4 ,5 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Sarcoma Dis Management Team, 1275 York Ave, New York, NY 10065 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Surg, Gastr & Mixed Tumor Serv, 1275 York Ave,H1220, New York, NY 10065 USA
[3] Weill Cornell Med Coll, Dept Surg, 1300 York Ave, New York, NY USA
[4] Mem Sloan Kettering Canc Ctr, Dept Med, Sarcoma Oncol Serv, 300 East 66th St, New York, NY 10065 USA
[5] Weill Cornell Med Coll, Dept Med, 1300 York Ave, New York, NY 10065 USA
关键词
Sarcoma; Liposarcoma; Myxoid liposarcoma; Pleomorphic liposarcoma; CDK4; MDM2; FUS-CHOP; Trabectedin; SOFT-TISSUE SARCOMA; RANDOMIZED PHASE-II; DEDIFFERENTIATED LIPOSARCOMA; MYXOID LIPOSARCOMA; LIPOMATOUS TUMORS; CELL LIPOSARCOMA; MDM2; PROMOTES; EXTREMITY; SUBTYPE; CHEMOTHERAPY;
D O I
10.1016/j.soc.2016.05.007
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
There are 3 biologic groups of liposarcoma: well-differentiated and dedifferentiated liposarcoma, myxoid/round cell liposarcoma, and pleomorphic liposarcoma. In all 3 groups, complete surgical resection is central in treatment aimed at cure and is based on grade. Radiation can reduce risk of local recurrence in high-grade lesions or minimize surgical morbidity in the myxoid/round cell liposarcoma group. The groups differ in chemosensitivity, so adjuvant chemotherapy is selectively used in histologies with metastatic potential but not in the resistant subtype dedifferentiated liposarcoma. Improved understanding of the genetic aberrations that lead to liposarcoma initiation is allowing for the rapid development of targeted therapies for liposarcoma.
引用
收藏
页码:761 / +
页数:14
相关论文
共 50 条
  • [1] Current management options for liposarcoma and challenges for the future
    Kollar, Attila
    Benson, Charlotte
    EXPERT REVIEW OF ANTICANCER THERAPY, 2014, 14 (03) : 297 - 306
  • [2] Pharmacological therapies for Liposarcoma
    Saponara, Maristella
    Stacchiotti, Silvia
    Gronchi, Alessandro
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (04) : 361 - 377
  • [3] New targeted therapies in liposarcoma: state of art and future perspectives
    Franza, Andrea
    Fabbroni, Chiara
    Pasquali, Sandro
    Casali, Paolo Giovanni
    Sanfilippo, Roberta
    CURRENT OPINION IN ONCOLOGY, 2024, 36 (04) : 291 - 296
  • [4] Liposarcoma: A Journey into a Rare Tumor's Epidemiology, Diagnosis, Pathophysiology, and Limitations of Current Therapies
    Jonczak, Emily
    Grossman, Julie
    Alessandrino, Francesco
    Seldon Taswell, Crystal
    Velez-Torres, Jaylou M.
    Trent, Jonathan
    CANCERS, 2024, 16 (22)
  • [5] Advances in the targeted therapy of liposarcoma
    Guan, Zhonghai
    Yu, Xiongfei
    Wang, Haohao
    Wang, Haiyong
    Zhang, Jing
    Li, Guangliang
    Cao, Jiang
    Teng, Lisong
    ONCOTARGETS AND THERAPY, 2015, 8 : 125 - 136
  • [6] Management of Synovial Sarcoma and Myxoid Liposarcoma
    Hindi, Nadia
    Haas, Rick L.
    SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA, 2022, 31 (03) : 547 - 558
  • [7] Medical management of unresectable, recurrent low-grade retroperitoneal liposarcoma: integration of cytotoxic and non-cytotoxic therapies into multimodality care
    Goss, G
    Demetri, G
    SURGICAL ONCOLOGY-OXFORD, 2000, 9 (02): : 53 - 59
  • [8] Pleomorphic Liposarcoma of the Extremity and Trunk: Multimodality Therapy for Some but Not All?
    Tseng, William W.
    Barretta, Francesco
    Tucci, Francesco
    Barisella, Marta
    Radaelli, Stefano
    Colombo, Chiara
    Callegaro, Dario
    Morosi, Carlo
    Sanfilippo, Roberta
    Fabbroni, Chiara
    Stacchiotti, Silvia
    Sun, Steven H.
    Collini, Paola
    Fiore, Marco
    Gronchi, Alessandro
    JOURNAL OF SURGICAL ONCOLOGY, 2024, : 291 - 297
  • [9] Surgical management of spinal liposarcoma: a case series of 7 patients and literature review
    Zhao, Chenglong
    Han, Zhitao
    Xiao, Hui
    Yang, Cheng
    Zhao, Yongfei
    Fan, Tianqi
    Sun, Zhengwang
    Liu, Tielong
    Xiao, Jianru
    EUROPEAN SPINE JOURNAL, 2016, 25 (12) : 4088 - 4093
  • [10] MDM2-p53 in liposarcoma: The need for targeted therapies with novel mechanisms of action
    Somaiah, Neeta
    Tap, William
    CANCER TREATMENT REVIEWS, 2024, 122